Next Article in Journal
Phenotypic Expression of Known and Novel Hemoglobin A2-Variants, Hemoglobin A2-Mae Phrik [Delta 52(D3) Asp > Gly, HBD:c.158A > G], Associated with Hemoglobin E [Beta 26(B8) Glu > Lys, HBB:c.79G > A] in Thailand
Next Article in Special Issue
Cellular Senescence in Normal Mammary Gland and Breast Cancer. Implications for Cancer Therapy
Previous Article in Journal
RNA m6A Modification Changes in Postmortem Nucleus Accumbens of Subjects with Alcohol Use Disorder: A Pilot Study
Previous Article in Special Issue
Potential Refinement of Recurrence Score by pSTAT3 Status
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 13
Issue 6
10.3390/genes13060960
Review Report
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

The History of Early Breast Cancer Treatment

Genes 2022, 13(6), 960; https://doi.org/10.3390/genes13060960
by Judith Ben-Dror 1, Michal Shalamov 2 and Amir Sonnenblick 1,2,*
Reviewer 1: Anonymous
Reviewer 2:
Raphael Catane
Genes 2022, 13(6), 960; https://doi.org/10.3390/genes13060960
Submission received: 1 May 2022 / Revised: 22 May 2022 / Accepted: 23 May 2022 / Published: 27 May 2022
(This article belongs to the Special Issue Molecular Therapeutics of Breast Cancer)

Round 1

Reviewer 1 Report

This is a comprehensive work and overview on the history of breast cancer treatment.

Some passages could be improved, see below. It also needs some editing (typos etc.).

  • 110: Sir George Thomas Beatson: Maybe mention that he first discovered the anti-hormone effect of an oophorectomy in rabbits, when he observed in lactating rabbits a stop in milk production after the surgery.
  • 144: You should also cite the ATTOM trial here.
  • 152: Please also mention the latest meta-analysis of the EBCTCG on this

                Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.

              

  • 161-168: Why do you not mention Ribociclib? To date, it is the only CDK4/6 inhibitor that has prolonged overall survival significantly in a total of three randomized trials (MonaLeesa-2/3/7), it deserves to be mentioned here.
  • 186: you could mention the NEO-ORB trial here.
  • Figure 1: Please re-name Aromasin to exemestane, as you mention anastrozole and letrozole, which both are substance names, too. There is a typo in Fulvestrant (SERD instead of SRED). A legend for the abbreviations is missing. If you mention all of the approved substances in this figure, you should mention ribociclib, too. Is there also a way to include sacituzumab-govitecan in this figure?
  • Figure 2: Typo in Talazoparib and Capecitabine. Again, include Ribociclib, please.
  • 283: It is unusual to use the trade name (Enhertu) instead of the substance name in a publication.
  • 291: predisposes some „women“ to develop the disease, not breast cancer patients yet.
  • A passage on sacituzumab-govitecan would be nice, too.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

This is an excellent review of the development of the treatment of breast cancer. It should be published ASAP as the treatment of breast cancer continues to evolve and if delayed the manuscript will have to be updated/

Author Response

Thank you for your comment

Back to TopTop